Recent Updates
Recently added Catalysts

Carlsmed, Inc.

CARLFDA catalysts, PDUFA dates & pipeline intelligence
$17.35
▲ +0.23 · +1.34%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CARL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $8.5052W HIGH $19.15
Volume
191.02 K
Value Traded
3.39 M
Short % Float
12.11%
Days to Cover
15.1
+8.1%Week
+27.01%1 Month
+25.91%3 Month
+58.74%6 Month

Cash Data

Unlock CARL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
475.46 M
EPS (TTM)
-1.46
P/E Ratio
-
Ent. Value
413.39 M
Total Shares
27.40 M
Float Shares
10.25 M
Insiders
62.59%
Institutions
21.70%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every CARL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CARL Catalyst Timeline

Dated clinical, regulatory and corporate events for Carlsmed, Inc.

Unlock the full CARL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CARL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all CARL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Carlsmed, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every CARL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every CARL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CARL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Bertolini JeffreyOfficer (Chief Operating Officer)Option 747 23,236 held$5.92 11/03/2026
Unlock the full CARL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PARKMAN HEALTHCARE PARTNERS LLC 0.6 % (20 %) 6.20 M 597.32 K 14.62% ( 76.19 K)
Unlock every fund holding CARL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CARL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CARL ownership
Insider and institutional ownership, quarter by quarter.

CARL Short Interest

Shares sold short, counted twice a month.

12.11%
Short % of Float
of tradable shares sold short
1.2M
Shares Sold Short
+13.4% vs prior count
15.1 Very high
Days to Cover
trading days of normal volume to buy every short share back
82.4K
Avg Daily Volume
the average used for days to cover
Unlock CARL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CARL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CARL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CARL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CARL ranks across every disease it competes in

Competitive Position is a premium feature
See how CARL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CARL News

-CARL
Nov 16, 2026
CARLConferences/Events
▲ +1.3%today

Carlsmed to Participate in Upcoming Investor Conferences

Carlsmed, Inc. announced its participation in upcoming investor conferences. The company focuses on AI-enabled personalized spine surgery solutions. Webcasts for these events will be available on its investor website. Carlsmed aims to enhance healthcare outcomes while reducing costs in spine surgery.

Read more →
-CARL
Nov 10, 2026
CARLGeneral
▲ +26.4%on this news

Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

Carlsmed reported a strong third quarter for 2026, with revenue of $21.6 million, marking a 65% increase year-over-year. The company raised its full-year revenue guidance to between $78 million and $80 million. Key highlights include a significant growth in its surgeon user base and new reimbursement for its lumbar fusion procedure. However, the company also reported a net loss of $12.2 million.

Read more →
-CARL
Oct 27, 2026
CARLConferences/Events

Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026

Carlsmed, Inc. will report its third quarter 2026 financial results on November 10, 2026. The announcement includes a conference call and webcast scheduled for 1:30 PM Pacific Time. The company focuses on AI-enabled personalized spine surgery solutions to enhance healthcare outcomes.

Read more →
-CARL
Oct 14, 2026
CARLGeneral

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

Carlsmed, Inc. has launched its aprevo® Lumbar Bi-lateral Posterior System at the NASS Annual Meeting. This system expands Carlsmed's technology platform, enabling a personalized approach to spine fusion. Surgeons have reported positive outcomes and increased patient specificity with the system. The technology utilizes AI to create tailored surgical plans.

Read more →
-CARL
Oct 2, 2026
CARLGeneral
▲ +7.2%on this news

Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Carlsmed, Inc. has granted stock options and restricted stock units to its new CFO and Chief Product and AI Officer as part of their employment inducements. The grants, approved by the Compensation Committee, aim to align the interests of the new executives with the company's long-term goals. The stock options and RSUs will vest over several years, promoting retention.

Read more →
-CARL
Oct 1, 2026
CARLGeneral

Carlsmed Appoints Tony Jarc as Chief Product and AI Officer

Carlsmed has appointed Tony Jarc, Ph.D., as Chief Product and AI Officer to lead the development of its next-generation technology platform for personalized spine surgery. This strategic move comes as the company aims to scale its innovations and improve patient outcomes. Jarc's extensive experience in AI and digital products is expected to bolster Carlsmed's market leadership.

Read more →
-CARL
Sep 28, 2026
CARLGeneral
▼ -6.1%on this newsshared move

Carlsmed Appoints Richard Heppenstall as Chief Financial Officer

Carlsmed has appointed Richard Heppenstall as its new Chief Financial Officer, succeeding Leo Greenstein. Heppenstall brings nearly 30 years of experience in finance and operations within healthcare and technology. The company reaffirms its revenue guidance for 2026, projecting a 50% growth over the previous year, supported by new product launches and reimbursement policies.

Read more →
-CARL
Sep 15, 2026
CARLGeneral

Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical

Carlsmed, Inc. has filed a patent infringement lawsuit against DeGen Medical in the U.S. District Court for South Carolina. The lawsuit claims that DeGen is infringing on eight of Carlsmed's patents related to spine surgery technology. Carlsmed seeks injunctive relief and damages, emphasizing its dedication to advancing spine surgery standards.

Read more →
-CARL
Sep 8, 2026
CARLGeneral

Carlsmed, Inc. Announces Chief Operating Officer Appointment

Carlsmed, Inc. has announced the promotion of Jeff Bertolini to Chief Operating Officer, effective immediately. Bertolini, who joined the company in 2024, has previously held senior roles in operations and technology. His leadership is expected to enhance Carlsmed's capabilities in personalized spine surgery solutions, aligning with the company's mission to improve healthcare outcomes.

Read more →
-CARL
Aug 5, 2026
CARLGeneral

Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance

Carlsmed, Inc. reported a strong second quarter for 2026 with revenues of $18.9 million, marking a 57% increase from the previous year. The company raised its full-year revenue guidance to between $74 million and $78 million, driven by robust growth in its AI-enabled spine surgery solutions. Notably, surgeon adoption has surged, and a recent CMS ruling is expected to further enhance reimbursement for their procedures.

Read more →
-CARL
Aug 3, 2026
CARLFDA Updates

Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures

Carlsmed, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy for aprevo® lumbar spinal fusion procedures. This decision, effective October 1, 2026, includes new MS-DRG assignments that will enhance hospital and patient access to the procedure. The CEO highlighted the importance of this policy in improving healthcare outcomes and reducing costs.

Read more →
-CARL
Jul 27, 2026
CARLConferences/Events
▲ +7.5%on this news

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

Carlsmed, Inc. has announced its participation in two upcoming investor conferences. The company will host one-on-one meetings at the 11th Annual Needham Virtual MedTech & Diagnostics Conference on August 10, 2026, and will participate in a fireside chat at the Bank of America SMID Cap Virtual Conference on August 12, 2026. These events highlight Carlsmed's commitment to engaging with investors and showcasing its AI-enabled personalized spine surgery solutions.

Read more →
-CARL
Jul 22, 2026
CARLConferences/Events

Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026

Carlsmed, Inc. announced it will release its second quarter 2026 financial results on August 5, 2026. The company, known for its AI-enabled personalized spine surgery solutions, will host a conference call and webcast to discuss the results. This event reflects the company's commitment to transparency with its investors.

Read more →
-CARL
May 6, 2026
CARLGeneral
▲ +10.3%on this news

Carlsmed® Reports First Quarter 2026 Financial Results

Carlsmed, Inc. reported a strong first quarter for 2026, achieving $16.1 million in revenue, a 58% increase from the previous year. The company raised its full-year revenue guidance to between $72 million and $77 million. Notably, clinical data published in the Global Spine Journal highlighted a significant reduction in revision rates for its product, aprevo®. The company is optimistic about its upcoming product launches and continued growth.

Read more →
-CARL
Apr 29, 2026
CARLConferences/Events

Carlsmed, Inc. To Participate in Upcoming Investor Conferences - April 28, 2026

Carlsmed, Inc. has announced that CEO Mike Cordonnier will participate in upcoming investor conferences. The company aims to improve healthcare outcomes through AI-enabled personalized spine surgery solutions. Live and archived webcasts of the presentations will be accessible on their investor relations website.

Read more →
-CARL
Apr 14, 2026
CARLConferences/Events
▲ +7.6%on this news

Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026

Carlsmed, Inc. has announced that it will report its first quarter 2026 financial results on May 5, 2026, after market close. The company will also host a conference call and webcast at 1:30 PM Pacific Time to discuss the results. This event reflects Carlsmed's commitment to transparency and investor engagement.

Read more →
-CARL
Feb 26, 2026
CARLGeneral
▲ +15.9%on this news

Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

Carlsmed, Inc. reported strong financial results for Q4 and full year 2025, with revenues of $15.2 million and $50.5 million respectively, reflecting year-over-year growth of 61% and 86%. The company achieved a gross margin of 76.5% and improved operational efficiency by reducing lead times. The CEO highlighted significant advancements in patient outcomes through their AI-enabled spine surgery solutions.

Read more →
-CARL
Feb 24, 2026
CARLConferences/Events

Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference

Carlsmed, Inc. announced its participation in the 2026 Canaccord Genuity Musculoskeletal Conference, where CEO Mike Cordonnier will present on March 2, 2026. The conference will take place in New Orleans, LA, and a live webcast will be available for registered participants. This event highlights Carlsmed's commitment to advancing spine surgery through AI technology.

Read more →
-CARL
Feb 12, 2026
CARLConferences/Events
▼ -5.8%on this news

Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Carlsmed, Inc. has announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026. The company, known for its AI-enabled personalized spine surgery solutions, will host a conference call and webcast at 1:30 PM Pacific Time on the same day. This event demonstrates the company's commitment to transparency with its investors.

Read more →

About Carlsmed, Inc.

Carlsbad, CA 127 employees carlsmed.com
Headquarters1800 ASTON AVENUE, CARLSBAD, CA, 92008
BIOPHARMAWATCH ELITE
Trade the next CARL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime